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Abstract: The purpose of this study was to investigate the feasibility and advantages of 
constructing a novel tissue engineering bone, using β-tricalcium phosphate (β-TCP) and rat 
bone marrow mesenchymal stem cells (MSCs), modified with human bone morphogenetic 
protein  2  gene  (hBMP2)  and  human  vascular  endothelial  growth  factor  165  gene 
(hVEGF165), through lentiviral transfection. Both genes were successfully co-expressed in 
the  co-transfection  group  for  up  to  eight  weeks  confirmed  by  enzyme-linked 
immunosorbent assay (ELISA). After seeding MSCs onto the scaffolds, scanning electron 
microscopy  (SEM)  observation  showed  that  MSCs  grew  and  proliferated  well  in  
co-transfection group at 7 and 14 days. There was no significant difference among all the 
groups in hoechst DNA assay for cell proliferation for 14 days after cell seeding (P > 0.05), 
but the highest alkaline phosphatase (ALP) activity was observed in the co-transfection 
group at  14  days after cell seeding (p <  0.01). These results  demonstrated that  it was 
advantageous  to  construct  tissue  engineering  bone  using  β-TCP  combined  with  MSCs 
lentivirally co-transfected  with  BMP2  and  VEGF165,  providing  an  innovative way  for 
treating bone defects. 
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engineering bone; vascular endothelial growth factor; β-tricalcium phosphate (β-TCP) 
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1. Introduction 
As an integration of ex vivo gene therapy and tissue engineering approach, gene modified tissue 
engineered bone has been recently reported to be an attractive option to treat bone defects [1–3]. Many 
of these studies have focused on bone morphogenetic protein 2 (BMP2) [4–6], which has the highest 
osteoinduction activity in vivo among the BMP family members [7]. In addition, vascular endothelial 
growth factor (VEGF), the most potent angiogenic growth factor, has also been specially chosen for 
several studies because vascularization appears to be a key factor in bone tissue engineering, especially 
for large and critical size bone defects [8–9]. 
Since  both  BMP2  and  VEGF  are  involved  in  bone  regeneration  as  osteogenic  and  angiogenic 
factors, it is possible that combined gene therapy of both genes in bone tissue engineering might have 
more significant effect on bone regeneration than single gene alone. Furthermore, there is concern that 
a single exposure to an exogenous growth factor may not induce an adequate osteogenic signal in 
many  clinical  situations  with  relatively  limited  bone  healing  potential  because  of  compromised 
vascularity, limited bone stock, and abundant fibrous tissue [10]. 
To address these important questions, we constructed tissue engineering bone using β-tricalcium 
Phosphate  (β-TCP)  combined  with  rat  bone  marrow  mesenchymal  stem  cells  (MSCs)  lentivirally  
co-transfected with human BMP2 gene (hBMP2) and human VEGF165 gene (hVEGF165), which had 
not  been  previously  experimentally  demonstrated.  Lentiviral  vector  mediated  transfer  system  was 
applied by virtue of its several advantages, such as high transfection efficiency, low toxicity and the 
ability to incorporate into the host genome allowing for prolonged target gene expression [11–12]. The 
feasibility of this co-transfection approach is supported by former combined gene therapy through  
co-transfection  of  other  genes  [13–14].  Cell  proliferation  and  osteogenic  differentiation  on  the 
scaffolds were evaluated by scanning electron microscopy (SEM) observation, hoechst DNA assay and 
alkaline phosphatase (ALP) activity assay. 
2. Results and Discussion 
2.1. ELISA 
In BMP+VEGF group, consistently high production of BMP2 and VEGF165 proteins was achieved 
for over eight weeks (Figure 1). At each time point, there was no significant difference in the amount 
of BMP2 production between BMP group and BMP+VEGF group (P > 0.05), whereas no detectable 
BMP2 was produced in control group and VEGF group. Similarly, there was no significant difference 
in the amount of VEGF165 production between VEGF group and BMP+VEGF group at each time 
point (P > 0.05), whereas no detectable VEGF165 was produced in control group and BMP group. 
In recent years, ex vivo gene therapy of MSCs genetically modified with BMP2 has emerged as an 
effective strategy for bone regeneration [5,15]. Although BMP2 gene therapy is still being investigated 
for its therapeutic potential, a combination of BMP2 and other growth factors may prove to be a more 
effective  initiator  of  bone  formation.  Because  bone  formation  requires  angiogenesis  within  newly 
formed tissue, it is possible that up-regulation of VEGF may also improve the efficacy of BMP gene 
therapy for bone regeneration. In a study by Peng, ex vivo gene therapy, using muscle-derived stem Int. J. Mol. Sci. 2011, 12                       
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cell mediated delivery of VEGF in combination with BMP-4 over-expression, induced more bone 
formation than either of the two genes individually [8].  
Figure 1. Supernatants of MSCs in each group (Control group, BMP group, VEGF group 
and  BMP+VEGF  group)  were  collected  at  1,  4,  and  8  weeks  after  transfection  and 
measured with ELISA kits specific for BMP2 (A) and VEGF165 (B). Results are shown as 
mean ±  SD (n = 4 for each group). 
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There  are  several  choices  of  vectors  for  ex  vivo  gene  transfer,  such  as  plasmids,  liposomes, 
retrovirus, adenovirus and adeno-associated virus [16]. To date, viruses are the most efficient vectors 
for gene delivery [17]. However, the use of these viral vectors has several disadvantages. For example, 
retroviral vectors require actively dividing cells for integration of the foreign gene. Transduction with 
adenoviral vectors is generally less efficient and requires very high vector doses [18] and the transient 
protein  production  may  not  produce  an  adequate  osteogenic  response  in  severely  compromised 
biological environments [19]. An ideal vector would have a high transfection efficiency, low toxicity, 
and  consistent  gene  expression.  Recently,  lentiviral  vectors  based  ex  vivo  gene  therapy  has  been 
developed  for  bone  regeneration  [17,20].  Lentiviral  vectors  can  transduce  both  dividing  and 
nondividing  cells  and  incorporate  into  the  host  genome,  allowing  for  prolonged  target  gene  
expression [12]. In McMahon et al.’s study, HIV-based lentivirus proved to be the most effective 
method  with  transduction  efficiencies  of  up  to  95%,  concurrent  with  low  levels  of  cell  toxicity 
compared with adenovirus, adeno-associated virus, and nonviral vectors at delivering GFP reporter 
gene into rat MSCs [11].  Int. J. Mol. Sci. 2011, 12                       
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In  our  study,  rat  MSCs  infected  with  Lv-GFP  demonstrated  over  90%  transduction  efficiency, 
which was in accordance with the result in McMahon et al.’s study. And the hoechst assay results 
showed  that  the  growth  curves  of  all  the  groups  were  similar,  indicating  that  lentivirus-mediated  
co-transferetion  did  not  inhibit  cell  proliferation.  ELISA  results  demonstrated  that  VEGF165  and 
BMP2  genes  were  successfully  co-expressed  with  significant  quantities  for  eight  weeks  in 
BMP+VEGF group, suggesting that the lentiviral vectors stably incorporated into the host genome and 
were passed on to all progeny cells in an expanding BMSCs population, leading to a long-term stable 
expression of exogenous gene rather than a single bolus or limited expression in only one generation. 
Prolonged gene expression may be necessary when developing tissue engineering strategies to repair 
large  bone  defects  especially  with  a  compromised  host  environment  that  is  often  seen  in  tumor 
resection, fracture nonunion, and revision total joint arthroplasty [17,20]. 
2.2. SEM Examination 
The morphology of MSCs co-transfected with BMP+VEGF on the scaffolds was observed by SEM 
at 7 and 14 days after cell seeding. At day 7, the cells adhered and differentiated well on the β-TCP 
scaffold  with  a  good  proliferating  capability  and  some  typical  osteoblast-like  cells  could  be  seen 
(Figure 2A). At day 14, it was observed that most of the pore surface was covered by cells together 
with numerous extracellular matrices (ECM) (Figure 2B). 
Figure 2. SEM images of MSCs on the β-TCP scaffolds (A) 3 days and (B) 7 days after 
cell seeding (Bar = 300 μm). 
 
 
Bone tissue engineering has been developed as the most researched alternative to conventional 
therapies for fracture nonunion, spinal fusion and segmental skeletal defects following tumor resection 
or trauma [21–23]. Typically, bone tissue engineering methods consist of three elements: a donor cell Int. J. Mol. Sci. 2011, 12                       
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source, a three-dimensional scaffold or matrix and osteoinductive growth factors [24]. Within this 
method, there is the potential to genetically modify the donor cells to express the required growth 
factors and the donor cells also need to be delivered in a scaffold. 
A suitable scaffold for bone tissue engineering is also critical for the success of any gene therapy 
strategy. β-TCP shows excellent osteoconductivity and biocompatibility, and its biodegradation rate 
could be easily controlled. The novel porous β-TCP scaffolds applied in this study has been proved to 
have  prominent  osteoconductive  activity  and  exhibited  good  osteogenic  activity  both  in  vitro  and  
in vivo with the aid of osteogenic medium in a previous study [25,26]. In our study, SEM findings 
confirmed that MSCs can easily adhere to, and proliferate inside, the β-TCP scaffolds. The DNA and 
ALP  activity  assay  results  also  indicated  that  the  novel  porous  β-TCP  scaffolds  can  support  the 
proliferation and subsequent osteogenic differentiation of rat MSCs in vitro.  
2.3. Hoechst DNA Assay 
Cell proliferation of MSCs for each group on the β-TCP scaffolds was determined by hoechst DNA 
assay for 14 days and the results are shown in Figure 3. The corresponding viable cell number of each 
group showed a similar trend and no significant difference could be found (P > 0.05). Viable cell 
number increased with time gradually during the first week of culture, peaked at day 7 or day 8 and 
then leveled off, following a plateau phase. However, the number of viable cells within the scaffolds 
still exhibited an increase of around 3-fold at day 14 compared to the initially seeding number. As for 
the safety profiles, the third generation HIV-1-based cloning vector system applied in our study was 
designed to  maximize its biosafety features including the development of self-inactivating vectors 
producing  pseudotyped  lentiviral  particles,  minimizing  the  chances  of  generating  
replication-competent virus via recombination by development of a three-plasmid expression system 
and so on, making it possible for lentiviral-based gene therapy in preclinical models and decreasing the 
potential dangers of its clinical use [27,28]. 
Figure 3. The proliferation curves of MSCs of each group (Control group, VEGF group, 
BMP group and BMP+VEGF group) on the β-TCP scaffolds. Cell proliferation of each 
group on the β-TCP scaffolds was determined every day by a hoechst assay for up to two 
weeks after cell seeding. Data are expressed as mean ±  SD (n = 3 for each group). 
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2.4. ALP Activity Assay 
The ALP activity result at 14 days after cell seeding is shown in Figure 4. The ALP activity was 
stimulated by 2.9-fold in VEGF group compared to that in control group (P < 0.01). In BMP group, the 
ALP activity was further stimulated by 8.3-fold compared to that in control group (P < 0.01); and the 
ALP activity was 1.6-fold greater in BMP+VEGF group compared to that in BMP group (P < 0.01). 
Figure 4. Detection of alkaline phosphatase (ALP) activity for each group (Control group, 
VEGF group, BMP group and BMP+VEGF group) at 14 days after cell seeding. Results 
are shown as mean ±  SD (n = 5 for each group). 
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ALP has been implicated as a marker of osteoblast differentiation which is expressed early in the 
process and its expression persists throughout the maturation of the osteoblast [29–31]. Gene delivery 
of BMP2 could augment the expression of alkaline phosphatase in BMSCs [15,32], which was in 
accordance with the results in our study. Liquid recombinant murine VEGF was reported to induce 
alkaline  phosphatase  activity  in  primary  human  osteoblasts  [33].  Midy  and  Plouet  noted  that  the 
alkaline phosphatase expression of fetal bovine osteoblasts was significantly increased when exposed 
to rhVEGF [34]. Treatment of KS483 cells (preosteoblast-like cell line) with rhVEGF-A, stimulated 
alkaline phosphatase nodule formation [35]. All the above research suggested that VEGF might have a 
direct autocrine role in osteoblast differentiation. In our study, the ALP activity was also significantly 
increased in MSCs infected with Lv-VEGF when compared to control group, but lower than that in 
BMP  group.  And  co-expression  of  BMSCs  with  BMP2  and  VEGF  resulted  in  an  increased  ALP 
activity than the BMP group. These observations implied that the stimulation of ALP activity in the  
co-transfected MSCs was the result of the synergistic action of endogenous BMP2 and VEGF proteins 
produced by double-transfected cells. Similar research by Yeh LC and Lee JC showed that significant 
enhancement of osteogenic cell differentiation evaluated by ALP activity could be accomplished by 
co-transfection with an osteogenic protein gene, such as osteogenic protein-1(OP-1) and an enhancer 
gene, such as insulin-like growth factor 1 (IGF-I) [36]. Int. J. Mol. Sci. 2011, 12                       
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3. Experimental Section 
3.1. MSCs Isolation and Expansion 
Rat bone marrow was obtained from the femurs and tibias of 2-week-old Wistar rats by a technique 
described previously [15], and cultured on tissue culture dishes (Falcon, BD Labware) in low-glucose 
Dulbecco’s  modified  Eagle’s  medium  (DMEM)  supplemented  with  10%  (v/v)  fetal  bovine  serum 
(FBS), 1% penicillin/streptomycin at 37 ° C in 5% CO2. All procedures were performed at the facility 
accredited by the Animal Care and Experiment Committee of Shanghai Jiao Tong University School 
of Medicine. MSCs can adhere to the surface of culture dishes (whereas hemopoietic cells cannot), so 
the  adherent  cells  were  isolated  from  bone  marrow  with  medium  changed  twice  a  week  through 
adherence-separation culturing. When reaching 80% confluency, cells were detached with 0.25% (w/v) 
trypsin/1mM EDTA solution (1:1,v/v), replated at 1× 10
4 cells/cm
2 on tissue culture dishes and cultured 
as first-passage cells (P1) until confluency (5–7 days). MSCs at passage 2 were used for transfection. 
3.2. Lentiviral Vector Construction, Virus Production, and Infection 
hBMP2 and hVEGF165 cDNAs were amplified from human osteosarcoma MG-63 cell line by 
polymerase chain reaction (PCR) using the primers described in Table 1. Then hBMP2 and hVEGF165 
cDNAs  were  subcloned  into  the  pCDH  expression  lentivector  (System  Biosciences)  respectively. 
293TN producer cells were co-transfected with pPACK Packaging Plasmid Mix (System Biosciences) 
and expression lentivector (containing hBMP2 or hVEGF165) or control green fluorescent protein 
(GFP)  plasmid  by  using  Lipofectamine™2000  (Invitrogen).  Thus,  the  lentivirus  containing  BMP2 
cDNA (Lv-BMP), lentivirus containing VEGF165 cDNA (Lv-VEGF) and lentivirus containing GFP 
cDNA (Lv-GFP) were obtained. 
Table 1. Primers of vascular endothelial growth factor 165 gene (VEGF165) and bone 
morphogenetic  protein  2  gene  (BMP2)  for  the  polymerase  chain  reaction  (PCR)  that 
amplified VEGF165 and BMP2 from human osteosarcoma MG-63 cell line. 
Gene Primers 
VEGF165 
5’-CGGAATTCGCCACCATGAACTTTCTGCTGTCTTGGGTGC-3’ (forward) 
5’-CGCGGATCCTCACCGCCTCGGCTTGTCACATC-3’ (reverse) 
BMP2  
5’-GGAATTCGCCACCTGCGGTCTCCTAAAGGTC-3’ (forward) 
5’-CGGGATCCTTGCTGTACTAGCGACACCCAC-3’ (reverse) 
Rat MSCs of passage2 in culture were infected with Lv-GFP at various multiplicity of infection 
(MOI) of 5, 10, 20, and 40. The efficiency of lentiviral gene transfer in MSCs was quantitatively 
determined  by  the  fraction  of  fluorescent  cells  with  fluorescent  microscopy  according  to  the 
manufacturer’s instructions (System Biosciences) at 4 days after transfection. As a result, the fraction 
of green-glowing cells reflecting the lentiviral gene transfer efficiency was dose dependent in the range 
of 5–40 MOI (data not shown). The highest transfection efficiency up to 90% was obtained at a MOI Int. J. Mol. Sci. 2011, 12                       
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of 40 (Figure 5), while flow cytometry studies demonstrated minimal apoptosis (data not shown). 
There  were  four  groups  in  this  study:  MSCs  not  infected  with  lentivirus  (Control  group),  MSCs 
infected with Lv-BMP (BMP group) at 40 MOI, MSCs infected with Lv-VEGF (VEGF group) at  
40 MOI, MSCs infected with Lv-BMP at 40 MOI and Lv-VEGF at 40 MOI (BMP+VEGF group). Rat 
MSCs  of  passage2  in  culture  were  infected  according  to  the  four  groups  described  above  in  the 
presence of 5 μg/mL polybrene (Sigma). 
Figure 5. Rat MSCs of passage2 in culture were infected with Lv-GFP at a MOI of 40. A 
transfection efficiency up to 90% was obtained, determined by the fraction of fluorescent 
cells with fluorescent microscopy at 4 days after transfection (Bar = 500 μm). 
 
3.3. Enzyme Linked Immunoabsorbent Assay (ELISA) 
The in vitro hBMP2 and hVEGF165 production in each group was quantified in culture supernatant 
at 1, 4, and 8 weeks after transduction using an ELISA kit (BMP2 ELISA kit, R&D system; VEGF165 
ELISA kit, BIOSOURCE) according to the manufacturer’s instructions. The medium was changed 
every 24 hours during the ELISA detection period. 
3.4. Preparation of Porous β-TCP Scaffolds and Cell Seeding 
The β-TCP scaffolds with dimensions of 3 mm ×  3 mm ×  3 mm were kindly provided by Shanghai 
Tissue Engineering Research and Development Center. The scaffold porosity is 90.7 ±  1.9%, with pore 
sizes ranging from 300 to 500 μm. The scaffolds with dimension of 3 mm ×  3 mm ×  3 mm were 
sterilized in an autoclave before use. 
MSCs of each group were collected and seeded at a density of 1 ×  10
6 in 30 L on the β-TCP 
scaffolds and incubated at 37 °C  for 2 h to allow cells to attach to the scaffolds. Then the scaffolds 
were transferred into a 96-well plate, respectively. Each well with one scaffold was cultured with the 
normal culture medium to form tissue engineering bone. The medium was changed every 2–3 days 
after cell seeding on the scaffolds. Int. J. Mol. Sci. 2011, 12                       
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3.5. Scanning Electron Microscopy (SEM) 
The β-TCP scaffolds combining MSCs of BMP+VEGF group were randomly chosen for SEM 
observation  at  7  and  14  days  after  cell  seeding.  Samples  were  firstly  fixed  with  2% 
parformaldehyde/2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4), postfixed for 48 h 
in 0.1% osmium tetroxide (OsO4), dehydrated through an ethanol series, and dried in a CO2 critical 
point dryer for 12 h. The samples were then sputter coated with gold and imaged at 15 keV with a 
scanning electron microscope (JSM-6360, JEOL, Japan). 
3.6. Hoechst DNA Assay 
Cell proliferation of each group was determined every day by a hoechst assay for up to two weeks 
after cell seeding. A DNA standard was prepared by lysing serial dilutions of a known concentration of 
MSCs. The amount of DNA within the scaffolds and standards was determined using Hoechst 33258 
dye. Fluorescence was measured at excitation wavelength 355 nm and emission wavelength 465 nm on 
a  fluorescence  plate  reader.  Cell  number  in  the  scaffolds  was  determined  by  comparing  sample 
fluorescent results to the cell standard curve. 
3.7. ALP Activity Assay 
The cell-seeded scaffolds of each group were analyzed 14 days after cell seeding as described 
below: The scaffolds were homogenized with 1mL Tris buffer (pH 7.4, Sigma), and sonicated. The cell 
lysate  (0.1  mL)  was  mixed  with  0.5  mL  p-nitrophenol  phosphate  substrate  solution  (Sigma)  and  
0.5 mL alkaline phosphatase buffer solution (Sigma). After incubation at 37 °C  for 15 min, 10 mL of 
0.05N NaOH were added to stop the reaction. The production of p-nitrophenol in the presence of ALP 
was measured by monitoring light absorbance of the solution at 405 nm at 1 min increments. The slope 
of the absorbance versus time plot was used to calculate the ALP activity.  
3.8. Statistical Analysis 
The experimental results were expressed as mean ±  SD. Student’s t-test was used to determine the 
statistical  significance  of  the  data  obtained.  Difference  with  P  <  0.05  was  considered  
statistically significant. 
4. Conclusions 
In  conclusion,  our  data  demonstrated  that  it  was  advantageous  to  construct  BMP2  and  VEGF 
modified tissue engineering bone through lentiviral transfection with a long-term stable co-expression 
of  both  genes  and  some  aspects  of  enhanced  osteogenic  differentiation,  thus  having  important 
implications for the new therapeutic strategies to enhance bone regeneration. Although both VEGF and 
BMP2 can stimulate osteogenic differentiation, the key advantage of local VEGF gene therapy may be 
its ability to couple angiogenesis with bone formation and remodeling in vivo. Whether the novel 
tissue  engineering  bone  will  enhance  bone  regeneration  in  vivo,  is  an  important  area  of 
experimentation and will be further studied. Int. J. Mol. Sci. 2011, 12                       
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